Kornimate/medical-research-clean huggingface dataset:
the immune tolerance mechanism induced by il-17-producing regulatory t cells in the orthotopic liver transplant recipients with aspergillosis

Conditions: Liver Transplantation; Aspergillus; Interleukin-17; Treg Cell; Immune Tolerance

Summary: infection accounted for the first cause of death in patients after liver transplantation, and 2 / 3 of the cause of death was fungal infections. the investigators group early found that t cell subsets playing a role of inducing immune tolerance were significantly increased in vivo of liver transplantation patients with aspergillus infection, which may be a kind of treg cells expressing il-17. to explore the immune tolerance mechanism induced by the immune balance cells is important to liver transplantation patients for improving efficacy and reducing the mortality. therefore, the investigators are going to get the blood sample and liver tissue of the liver transplantation patients before and after treatment of aspergillus infection, flow cytometry analysis of blood t cell subsets, cytometric bead array to detect changes in blood cytokines, laser capture microdissection to obtain liver biopsies of inflammatory cells in portal area and further for analysis of t cell subsets and protein. and the investigators are also to investigate the characteristics of ccr6 + cd4 + foxp3 + treg cell clones secreting il-17 and the capacity of which suppressing conventional t cell proliferation. this study may find new methods, such as certain types of t cell subsets or cytokines for the treatment of liver transplant patients, which not only to anti-rejection but also to reduce fungal infection.


Eligibility criteria:
inclusion criteria: liver transplantation patients exclusion criteria: psychopath

Keywords: liver transplantation aspergillus infection interleukin-17 treg cell immune tolerance
assessing the impact of movalis in osteoarthritis and rheumatoid arthritis patients on health related quality of life

Conditions: Osteoarthritis; Arthritis, Rheumatoid

Summary: the objective of the observational study is to examine the effect of movalis (meloxicam) therapy on health related quality of life (hrqol) in the diverse region of central and eastern europe. the medical outcomes study 12 item short form health survey version 2 (sf-12v2) will be used as the instrument to measure any change in physical wellbeing (physical component summary, pcs) and mental wellbeing (mental component summary, mcs) of patients following movalis (meloxicam) therapy.


Eligibility criteria:
inclusion criteria (according to summary of product characteristics (spc) ): 1. male or female patients aged 18 years or above 2 females of child bearing age must be using adequate contraception (hormonal or barrier method of birth control) 3. patients with symptoms of acute, painful osteoarthritis or rheumatoid arthritis 4. patients requiring therapy with non-steroidal anti-inflammatory drugs (nsaids) 5. patients requiring either parenteral and/or oral nsaids 6. patients who have not taken another nsaid or cyclo-oxygenase-2 (cox-2) inhibitor in the previous 7 days pain intensity on the visual analogue scale (vas) 25 mm and above exclusion criteria (according to contraindications of summary of product characteristics (spc) ): 1. known hypersensitivity to meloxicam or any excipient of the product, known or suspected hypersensitivity to analgesics, antipyretics or nsaids 2. patients who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other nsaids 3. active peptic ulcer, gastrointestinal perforation or bleeding within the last 6 months 4. severe liver failure 5. non-dialysed severe renal failure 6. pregnancy or breastfeeding 7. haemostasis disorders or concomitant treatment with anticoagulants 8. severe congestive heart failure
dysport in vulvodynia phase ii study

Conditions: Vulvodynia

Summary: this study is designed to define optimal doses of dysport and evaluate its efficacy and safety compared with placebo for the treatment of vulvodynia. the study will consist of a dose escalation stage (stage 1) and a dose expansion stage (stage 2). both stage 1 and stage 2 will consist of a double-blind period (with treatment cycle 1; dysport or placebo) followed by an open label treatment period. one or two optimally safe and effective doses of dysport selected from stage 1 will be further investigated in the stage 2.


Eligibility criteria:
inclusion criteria: * premenopausal * have vulvodynia for at least 6 months and for no more than 15 years * have provoked pain at the vestibule on a q tip test exclusion criteria: * deep pain during intercourse * have genitourinary or gastrointestinal conditions which may interfere with the study * previous surgery that according to investigator's judgement may impact on study outcome (including but not limited to hysterectomy, vestibulectomy, urologic surgery, perianal surgery) or genital trauma or mutilation/cutting
pharmacokinetics study of asciminib in subjects with impaired renal function compared to matched healthy volunteers

Conditions: Renal Impairment

Summary: the purpose of this study is to characterize the pharmacokinetics (pk) and safety profile of asciminib following a single oral dose in adult subjects with renal impairment compared to a matched group of healthy subjects with normal renal function. the results will determine whether or not a dose adjustment should be recommended when treating patients with asciminib who have impaired renal function.


Eligibility criteria:
inclusion criteria: * male or sterile / post-menopausal female * bmi between 18 and 36 kg/m2, body weight greater than or equal to 50 kg and no more than 120 kg * adequate venous access for blood sampling * for healthy volunteers: subject must be matched to at least one renal impaired subject by age (+/- 10 years), body weight (+/- 20%) and gender * for renal impaired subjects: documented stable renal disease without evidence of progressive decline in renal function (stable renal disease is defined as no significant change, such as, stable agfr \< 90, for 12 weeks prior to study entry) exclusion criteria: * women of child-bearing potential / pregnant / nursing * contraindication or hypersensitivity to any drug or metabolites from similar class as asciminib or to any excipients of the study drug * cardiac or cardiac repolarization abnormality * history of psychiatric illness within the past 2 years * history of acute or chronic pancreatitis * subject on dialysis * smokers (use of tobacco products in the previous 3 months) and not willing to abstain from using tobacco during the study * any surgical or medical condition altering the absorption, distribution, metabolism or excretion of drug * history of immunodeficiency diseases, including a positive human immunodeficiency virus (hiv) test result at screening * chronic infection with hepatitis b virus (hbv) or hepatitis c virus (hcv) at screening * donation or loss of 400 ml or more of blood or plasma within 8 weeks prior to dosing or other amount considered to compromise the health of the subject if previous history of anemia exists * use of the following drugs within 28 days prior to dosing: drugs that prolong the qt interval; cyp3a4 inhibitors and inducers; bcrp, ugt and pgp inhibitors and inducers other protocol-defined inclusion/exclusion criteria may apply

Keywords: abl001 asciminib impaired renal function pharmacokinetics
a study to evaluate and compare injections of autologous dermal and epidermal cells into the balding scalp of subjects with hair loss (ca-0004669)

Conditions: Androgenetic Alopecia; Male Pattern Baldness; Female Pattern Baldness

Summary: evaluate the injections of ji gami(tm) and ji gami(tm) do, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.


Eligibility criteria:
inclusion criteria: * male and female volunteers 18 to 65 years old, inclusive * hair loss consistent with ≥ grade iii-vertex, iv, va, v, and vi, based on norwood-hamilton scale providing there is bridging of hair in the anterior edge of the vertex circle. * have no clinically significant disease or abnormal laboratory results taken at the screening visit. * agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study. exclusion criteria: * known sensitivity to dmem/f-12 or any component of the study material. * known hypersensitivity to clindamycin hydrochloride, amphotericin b or streptomycin sulfate. * subjects who have used minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening. * a history of drug or alcohol abuse within 1 year of study enrollment. * clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator. * any clinically significant abnormal laboratory parameters. * a positive result at screening for human immunodeficiency virus (hiv 1 or 2), hepatitis b or c, htlv i/ii. * dermatologic condition in donation or study areas. * prior surgery in the treatment area. * insufficient hair or scarring in the donor area that might impact cell growth. * any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.

Keywords: androgenetic alopecia male pattern baldness female pattern baldness hair loss baldness
patient education and use of post operative pain medication in ambulatory hand surgery: a randomized controlled trial

Conditions: Ambulatory Hand Surgery

Summary: there is a current opioid epidemic in the united states partially fueled by excess prescribing practices after surgery. the objective of this study is to decrease the amount of opioids needed after ambulatory hand surgery. in this randomized control trial, patients will be randomized into a patient education group and into a control group. the education group will be provided with a pre-operative video detailing proper indications for opioid use after hand surgery, alternative pain management strategies to try before using prescription opioid medications, and side effects associated with opioid use. patients will also receive information on the current opioid epidemic. patients will be reminded of the information given pre-operatively after surgery in the post-anesthesia care unit. the control group will not receive pre-operative education and will only receive standard of care post-operative counseling by nursing in the post-anesthesia care unit. all patients will be given a pain log, pain medication diary and participate in phone/email surveys to determine number of opioid pills taken, pain levels, and satisfaction with surgery. the investigators hypothesize that the education group will have decreased opioid intake and increased patient satisfaction compared to the control group.


Eligibility criteria:
inclusion criteria: * english speaking: must be able to communicate over the phone or by email to perform questionnaires * primary elective ambulatory hand surgery (bony or soft tissue) bony: scaphoidectomy/ligament reconstruction tendon interposition (lrti), arthrodesis, arthroplasty soft tissue: carpal tunnel release (ctr), trigger finger (tf), dequervain's (dq), cyst removal, cubital tunnel, dupuytren's, tendon transfer, arthroscopy of wrist or elbow exclusion criteria: * disability or preop pain in ipsilateral upper extremity from a secondary condition not related to the study procedure * allergy or inability to consume oxycodone, percocet or vicodin due to a particular health state * current substance abuse * hss employees
comparison between elliptical domed mesh technique and lichtenstein technique in inguinal hernia

Conditions: Inguinal Hernia

Summary: the investigators describe a new surgical technique for inguinal hernia open repair, which will be compared with the lichtenstein technique. the investigators seek to find the difference between the two techniques in postoperative pain.

the investigators randomly assigned 168 adult patients with uncomplicated primary inguinal hernia to two treatment groups: group a: 84 patients treated with the new technique group b: 84 patients treated with the technique of lichtenstein (gold standard) the investigators reviewed the patients operated on one week, one month, three months and six months after surgery. the investigators evaluated the presence of moderate to severe pain in each technique, as well as the intensity of pain, measured by visual analogue scale. the investigators also determined the presence of inguinal dysesthesias in each technique, measured by dermatome mapping.

Eligibility criteria:
inclusion criteria: * adult patients diagnosed with uncomplicated primary inguinal hernia * mentally healthy patients * patients without preoperative groin pain * patients eligible for outpatient surgery exclusion criteria: * patients with different surgical diagnosis

Keywords: inguinal hernia pain inguinodynia mesh
efficacy of dexmedetomidine vs midazolam for early extubation in critically ill agitated patients undergoing weaning

Conditions: Agitation, Emergence

Summary: comparison of effect of dexmedetomidine and midazolam in icu patients who put on mechanical ventilation and show agitation on weaning.selection of better agent minimises the drug related side effects like respiratory depression but also helps in weaning for early extubation,give hemodynamic stability and reduce morbidity and mortality in icu..


Eligibility criteria:
inclusion criteria: * all patients with age \<60 irrespective of gendre exclusion criteria: - patients who refuse to give consent, severely altered conscious level (gcs \< 8/15), traumatic injury causing hypoxemia e.g., severe head / chest / facial trauma or pneumothorax, severe pneumonia, arrhythmia, impaired hearing or blindness, severe hepatic or renal disease, on neuromuscular blocking agents, recent myocardial infarction, use of anti-psychotics, hypersensitivity to any of the drug under study.
prospective registry of patients undergoing cardiac ct with naeotom alpha pcd-ct before tavi procedure

Conditions: Coronary Artery Disease; Aortic Valve Stenosis; Tomography, X-Ray Computed

Summary: the clinical and demographic characteristics of patients undergoing transcatheter aortic valve implantation (tavi) pose unique challenges for coronary computed tomography (ct) imaging, as this patient population is mainly composed of elderly, frail individuals with severe aortic stenosis, multiple comorbidities, high prevalence of heavily calcified coronary artery disease (cad) and revascularized coronary arteries. such vulnerable patients could benefit from a more precise assessment and characterization of their cad with ultra-high resolution (uhr) photon-counting detector (pcd) ct that would potentially avoid the need for pre-implantation invasive coronary angiography (ica). this international multicenter prospective registry study aims to investigate the feasibility and diagnostic accuracy of pcd-ct in the assessment of cad in the high-risk population of patients undergoing tavi, as compared to ica.


Eligibility criteria:
inclusion criteria: * clinically indicated tavi * clinically indicated ct and invasive coronary angiography * there are no contraindications to ct angiography. * understanding and signing the consent form exclusion criteria: * pregnancy or breastfeeding * chronic renal failure (egfr \<30 ml/m2) * active oncological treatment * any condition for which tavi is contraindicated and therefore no prior radiological investigation of tavi is indicated

Keywords: photon-counting detector computed tomography
sofa and apache ii scoring systems for predicting outcome of neurological patients admitted in a tertiary hospital intensive care unit

Conditions: Neurologic Disorder

Summary: the aim of this study was to compare the discriminative power of commonly used scoring systems, namely the sequential organ failure assessment (sofa) and acute physiology and chronic health evaluation ii (apache ii) in the intensive care unit of a tertiary care hospital.

this was a retrospective cross-sectional study including patients admitted to the icu of tu teaching hospital with a neurological diagnosis from january 1, 2022, to december 31, 2022. this study uses data collected prospectively as part of the nepal intensive care research foundation (nicrf) dataset. the icu database contained information for all components of the apache ii and sofa score with physiological data collected for the length of icu, and hospital stay. both sofa and apache ii were calculated from the admission data or if not available from the earliest data recorded after admission in icus.

Eligibility criteria:
inclusion criteria: * patients admitted with neurological diagnosis in icus exclusion criteria: * patients with missing data * patients with icu length of stay \< 24 h
toric intraocular lens following cataract surgery

Conditions: Cataract; Astigmatism

Summary: the objective of this clinical trial is to evaluate the safety and effectiveness of the bausch + lomb toric accommodating posterior chamber silicone intraocular lens used to provide near, intermediate, and distance vision and a reduction of the effects of preoperative corneal astigmatism in presbyopic patients undergoing cataract extraction and intraocular lens (iol) placement.


Eligibility criteria:
inclusion criteria: * subjects must have a clinically documented diagnosis of age-related cataract * subjects must require a lens power from 16 to 27 diopters * subjects must have predicted post-operative corneal astigmatism between 0.83d and 2.50d, as determined by the toric calculator exclusion criteria: * subjects with any anterior segment pathology for which extracapsular/ phacoemulsification cataract surgery would be contraindicated. * subjects with diagnoses of degenerative visual disorders. * subjects with conditions associated with increased risk of zonular rupture. * subjects who have had previous corneal surgery in the planned operative eye. * subjects with irregular corneal astigmatism. * subjects with clinically significant retinal pigment or epithelium/macular changes. * subjects with chronic use of systemic steroids or immunosuppressive medications. * subjects either concurrently participating in another clinical trial or have participated in another clinical trial within 60 days prior to enrollment in this study. * subjects with a difference in corneal astigmatism measured with the iol master and the topographer greater than 0.5 d using vector analysis.
preventive arterial wall phenotype and low-dose fluvastatin/valsartan combination

Conditions: Atherosclerosis

Summary: the study was designed to test whether short-term treatment with a very low-dose combination of fluvastatin and valsartan could induce improvement of endothelial function, arterial stiffness, vascular inflammation, oxidative stress and expression of protective genes in subjects with moderate cardiovascular risk.

the largest population that suffers from cardiovascular events are subjects at moderate cardiovascular risk. however, no effective and safe preventive treatment is available for this population. this study aimed to investigate whether their arterial wall phenotype could be turned to a preventive direction by low-dose fluvastatin/valsartan combination (low-flu/val). twenty males at moderate cardiovascular risk (as classified by score) were blindly randomised into the intervention group (n=10, low-flu/val: 10 mg/20mg) or control group (n=10, placebo). at inclusion and after 30 days of treatment, brachial flow-mediated dilatation (fmd), beta stiffness coefficient, carotid pulse wave velocity (c-pwv), carotid-femoral pwv, reactive hyperaemia index, high-sensitivity c-reactive protein (hs-crp), interleukin 6, vascular cell adhesion molecule 1, total antioxidant status and expression of several protective genes (sirt1, mtor, nf-κb1, nfe2l2, prkaa1) were followed.

Eligibility criteria:
inclusion criteria: * moderate cardiovascular risk according to systematic coronary risk estimation (score) risk charts of the european society of cardiology * males * aged between 40 and 55 years exclusion criteria: * diabetes mellitus * manifest peripheral artery disease or carotid artery disease * acute infection * chronic diseases * present therapy with fluvastatin and/or valsartan

Keywords: arterial stiffness endothelial dysfunction fluvastatin valsartan inflammatory markers oxidative stress sirt1
floseal tubeless exit versus cope loop nephrostomy versus fascial stitch following percutaneous nephrolithotripsy

Conditions: Kidney Calculi

Summary: the patient will be asked to participate in a research project designed to determine the best way to prevent bleeding and promote patient comfort after having kidney stones removed. two standard methods for ending the surgery are being compared to a newer method. in one standard method, the patient will have a tube draining urine from the kidney after the procedure. this tube may also prevent bleeding from the kidney. in another standard method the patient will have a tube left internally that drains urine from the kidney to the bladder and a stitch will be used to close the incision and deeper tissues in the back. in the third potential option, a tube would be left internally to drain urine from the kidney to the patient's bladder and the surgical site would be filled with a clot promoting agent (floseal) which is a fda approved agent specifically formulated to stop bleeding during surgical procedures.


Eligibility criteria:
inclusion criteria: * the patient has kidney stones that require treatment (tx) with percutaneous stone removal * 18 years of age or over exclusion criteria: * patient mentally impaired, have a chronic pain syndrome or disorder, or any condition that might alter the sensation of pain * patient taking coumadin * pre-existing percutaneous nephrostomy

Keywords: kidney stone removal surgery